CD274 and neoplasm: By targeting pathways such as PD-1/PD-L1 and CTLA-4, ICB therapy reinvigorates T cell-mediated anti-tumor responses and bolsters immune memory, providing a supportive TME for the formation and accumulation of TLSs 2.